Meta-Herpetic Keratitis and Therapeutic Approach: Case Report

Ozlem Sahin
Department of Ophthalmology/Uveitis, DunyaGoz Hospital Ltd., Ankara, Turkey
Email: ozlem1158@yahoo.com

Received 27 May 2014; revised 30 June 2014; accepted 23 July 2014

Copyright © 2014 by author and Scientific Research Publishing Inc.
This work is licensed under the Creative Commons Attribution International License (CC BY).
http://creativecommons.org/licenses/by/4.0/

Abstract

The purpose of this study is to disclose the steps in the therapeutic approach for meta-herpetic corneal ulcer. Report of a case with anterior segment photography was used. The 6 months of follow-up results of the case were disclosed. The efficacy of the therapeutic approach for meta-herpetic corneal ulcer was discussed.

Keywords
Corneal Ulcer, Corneal Neovascularization, Herpes Simplex Virus-1, Meta-Herpetic Keratitis

1. Introduction

Herpes simplex virus type 1 (HSV-1) is regarded as a common cause of keratitis [1]. The clinical types of keratitis caused by HSV-1 is classified as epithelial keratitis, (dendritica, geographica) stromal keratitis, (necrotizing, non-necrotizing) endotheliitis, (disciform keratitis) meta-herpetic keratitis, (neurotrophic keratopathy) and vascularized corneal scars [1]. Meta-herpetic corneal disease is considered as a chronic or chronic recurrent superficial post-herpetic corneal inflammation without any detectable HSV-1-activity [2]. Meta-herpetic erosion, ulcer and bullous keratopathy are the main types of meta-herpetic corneal disease [2]. Metaherpetic corneal inflammation is widely considered a therapeutic challenge. The purpose of this study is to disclose the steps in the therapeutic approach for meta-herpetic corneal ulcer.

2. Case Report

75-year-old male admitted with the symptoms of redness, tearing, photophobia and blurred vision in the right eye. He had a history of right recurrent HSV-1 epithelial keratitis in the last 2 years. He had been treated with only topical antiviral medications. The last episode of HSV-1 epithelial keratitis was 6 months ago. Best corrected visual acuities (BCVA) on admission were 20/400 in the right eye and 20/20 in the left eye. The intra-
Ocular pressures were 10 and 8 mm Hg respectively. Biomicroscopic examination of the right eye disclosed a centrally located deep corneal ulcer with smooth edges associated with stromal inflammation, descemét’s folds and 270 degrees of peripheral corneal neovascularization 1 - 5 mm from the limbus (Figure 1). He had a posterior chamber intraocular lens. (PCIOL) Biomicroscopic examination of the left eye disclosed a PCIOL and fundus examination of both eyes were normal. The corneal scraping specimens for bacterial and fungal cultures were negative. He was diagnosed as meta-herpetic corneal ulcer in the right eye. Treatment with valacyclovir 1000 mg twice a day, fibronectin drops prepared from the patient’s serum, sustained release doxycycline, vitamin C, loteprednol etabonate (LE) associated with frequent use of preservative free artificial tears were initiated. Biomicroscopic examination at the 3rd week of follow-up revealed the healing of corneal ulcer, decrease stromal inflammation with the resolution of descemét’s folds and diminished peripheral corneal neovascularization (Figure 2). He received the same treatment with decreasing doses of LE for 6 months. His examination at the 6th month of treatment revealed an increase in BCVA of the right eye to 20/40. Right cornea disclosed a central deep stromal scar without inflammation and neovascularization associated with sub-epithelial irregularities (Figure 3).

Figure 1. Anterior segment photo of the right cornea. Note centrally located deep corneal ulcer with smooth edges associated with stromal inflammation, descemét’s folds and peripheral corneal neovascularization.

Figure 2. Anterior segment photo of the right cornea in the 3rd week of follow-up. Note healing of the corneal ulcer, decreased stromal inflammation with the resolution of descemét’s folds and diminished peripheral corneal neovascularization.

Figure 3. Anterior segment photo of the right cornea at the 6th month of follow-up. Note a central deep stromal scar without inflammation and corneal neovascularization associated with sub-epithelial irregularities.
3. Discussion

Meta-herpetic keratitis is described as a structural damage by the immune and inflammatory mechanisms in the aftermath of HSV-1 corneal infection [3]. The rupture of the Bowman’s membrane with collagenases is shown to make the deep corneal ulcer possible [4]. Diagnosis of meta-herpetic keratitis is primarily based on a prior history of HSV-1 keratitis [5]. Serological investigations are not usually necessary [5]. This case had a history of recurrent epithelial keratitis treated with only topical antiviral medications. However, oral acyclovir has been recommended for the treatment of recalcitrant epithelial, stromal or uveal diseases secondary to HSV-1 [6]. The patient received inadequate treatment for recurrent HSV-1 keratitis. Diagnosis of meta-herpetic keratitis in this case was made on the basis of his prior history, biomicroscopic findings of deep ulcer with smooth edges associated with stromal inflammation, peripheral corneal neovascularization, and no growth of bacteria or fungi from the corneal scraping specimens. Treatment of meta-herpetic keratitis is challenging. Topical steroids are generally contraindicated in the presence of HSV epithelial keratitis [5] [6]. However, judicious topical steroid therapy is considered beneficial when combined with protective anti-viral coverage [5] [6]. The patient was treated with LE 0.5% five times a day. LE was shown to be highly lipophilic, and the highest concentrations of LE were reported to be found in the cornea followed by the iris, ciliary body and the aqueous humor [7]. Previous studies related to comparison of oral anti-viral therapy with valacyclovir or acyclovir revealed similar anti-viral potencies with less frequent dosages of valacyclovir [8] [9]. Valacyclovir 500 - 1000 mg twice a day is found as effective as acyclovir 200 mg five times a Day [9]. Valacyclovir has been recommended for the patients having difficulty in complying with the acyclovir doses [10]. The patient received valacyclovir 1000 mg twice a day with clinical improvement in 6 months. The expression of matrix metalloproteinase (MMPs) by resident corneal cells or by inflammatory cells has been disclosed in experimental HSV-1 keratitis [12]. MMPs have been considered to promote epithelial keratitis, ulcerative process and stromal liquefaction after corneal HSV-1 infection [12]. Combining antiviral therapy with MMPs inhibitors has been revealed to speed corneal healing [13]. MMPs inhibitors are considered to inhibit corneal neovascularization by inhibiting the expression of vascular endothelial growth factor and the interleukin-1β [14] [15]. This case received sustained release doxycycline for 6 months. The deep central corneal ulcer and peripheral corneal neovascularization were resolved with this treatment at the end of 6th month. Topical or systemic administrations of vitamin C or ascorbic acid have been shown to reduce corneal stromal inflammation through inhibition of polymorphonuclear leukocytes by the previous studies [16] [17]. The patient was treated with vitamin C orally for 6 months to promote the healing of the corneal ulcer. In conclusion; meta-herpetic keratitis is difficult to treat. We recommend early onset of systemic antiviral therapy in conjunction with smart use of topical steroids, MMPs inhibitors, vitamin C, fibronectin eye drops and preservative free lubricants.

Funding

Author does not have grants or funds in support of the study.

References


Scientific Research Publishing (SCIRP) is one of the largest Open Access journal publishers. It is currently publishing more than 200 open access, online, peer-reviewed journals covering a wide range of academic disciplines. SCIRP serves the worldwide academic communities and contributes to the progress and application of science with its publication.

Other selected journals from SCIRP are listed as below. Submit your manuscript to us via either submit@scirp.org or Online Submission Portal.